Asianet Newsable on MSN5h
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars
Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...
Vivani Medical Gives Data for Weight Loss Implant
By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...
Vivani Withers on Data Release
Vivani Medical, Inc. (NASDAQ: VANI) shares dropped in price Wednesday, as the Alameda, Calif.-based clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Vivani Medical announces preclinical weight loss data for NPM-139
Vivani Medical (VANI) announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight ...
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...